{"created":"2023-05-15T09:08:48.400599+00:00","id":16477,"links":{},"metadata":{"_buckets":{"deposit":"ec36a679-2fad-49dd-b567-6d83ee2bb01d"},"_deposit":{"created_by":14,"id":"16477","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"16477"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00016477","sets":["1875:1978:2194"]},"author_link":["32597","32598","32599","32600","32601","32602","32603","32604","32605","32606","32607","32608","32609","32610","32611","32612"],"control_number":"16477","item_2_biblio_info_6":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"187","bibliographicPageStart":"181","bibliographicVolumeNumber":"75","bibliographic_titles":[{"bibliographic_title":"市立札幌病院医誌"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Aim: Oral chemotherapy regimens of capecitabine plus oxaliplatin (XELOX/CapeOX) are preferable to continuous administration of intravenous 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX), and are widely favored by colorectal cancer (CRC) patients for convenience and flexibility. However, these therapies have a number of inherent disadvantages, including compliance requirements and delayed discovery of severe adverse events (SAEs) such as neutropenia and hand-foot skin reaction (HFSR) . So we designed a single-institutional prospective observational study to evaluate whether telephone intervention was useful in reducing the incidence of HFSR among Japanese outpatients with metastatic CRC (MCRC) who were undergoing oral chemotherapy involving the use of capecitabine.\nMethods: The subjects were CRC patients aged over 20 years who were undergoing oral chemotherapy involving the use of capecitabine. Eligible patients received periodic telephone intervention at 8, 15, 22, 29, 36 and 43 days after the treatment started. The primary endpoint was the incidence rate of grade 3 HFSR during three cycles of capecitabine administration. Secondary endpoints included the premature withdrawal rate, the treatment interruption rate, time to recovery from HFSR after interruption, mean cumulative dose, mean treatment duration, compliance, and phone call duration.\nResults: Between June 2010 and May 2012, a total of 20 eligible patients were enrolled. The incidence rate of grade 3 HFSR was 0%, and there was no withdrawal of administration due to HFSR. The average relative dose intensity of capecitabine was 94.3% (range: 75.0 - 101.6%).\nConclusion: Telephone intervention for Japanese CRC patients undergoing oral chemotherapy suppressed the incidence rate of severe HFSR.","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立札幌病院"}]},"item_2_version_type_15":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Michiko, Nakamura"}],"nameIdentifiers":[{"nameIdentifier":"32597","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hiromi, Takaguchi"}],"nameIdentifiers":[{"nameIdentifier":"32598","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Asuka, Yamamoto"}],"nameIdentifiers":[{"nameIdentifier":"32599","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Taichi, Murai"}],"nameIdentifiers":[{"nameIdentifier":"32600","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chika, Matsuda"}],"nameIdentifiers":[{"nameIdentifier":"32601","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ayano, Oba"}],"nameIdentifiers":[{"nameIdentifier":"32602","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kazufumi, Itaya"}],"nameIdentifiers":[{"nameIdentifier":"32603","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Taku, Shigesawa"}],"nameIdentifiers":[{"nameIdentifier":"32604","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuta, Koiko"}],"nameIdentifiers":[{"nameIdentifier":"32605","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yomo, Fujita"}],"nameIdentifiers":[{"nameIdentifier":"32606","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ayano, Endo"}],"nameIdentifiers":[{"nameIdentifier":"32607","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuko, Tsukuda"}],"nameIdentifiers":[{"nameIdentifier":"32608","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuji, Ono"}],"nameIdentifiers":[{"nameIdentifier":"32609","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahiko, Kudo"}],"nameIdentifiers":[{"nameIdentifier":"32610","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsushi, Nagasaka"}],"nameIdentifiers":[{"nameIdentifier":"32611","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shuji, Nishikawa"}],"nameIdentifiers":[{"nameIdentifier":"32612","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-25"}],"displaytype":"detail","filename":"l4256752181.pdf","filesize":[{"value":"15.9 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"l4256752181.pdf","url":"https://sapmed.repo.nii.ac.jp/record/16477/files/l4256752181.pdf"},"version_id":"155ad542-b896-4b69-9a9b-ab8a12d3bfd6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"capecitabine","subitem_subject_scheme":"Other"},{"subitem_subject":"colorectal cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"hand-foot skin reaction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"oral chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"telephone support","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Telephone support for capecitabine management in Japanese colorectal cancer patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Telephone support for capecitabine management in Japanese colorectal cancer patients","subitem_title_language":"en"}]},"item_type_id":"2","owner":"14","path":["2194"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-02-25"},"publish_date":"2020-02-25","publish_status":"0","recid":"16477","relation_version_is_last":true,"title":["Telephone support for capecitabine management in Japanese colorectal cancer patients"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2024-11-29T05:01:27.480659+00:00"}